Fig. 5.
The distribution of 1570 cytogenetic rearrangement breakpoints (850 constitutional and 720 malignancy-associated) from 1440 patients with defined phenotypes; 440 rearrangement breakpoints have been characterized at the molecular level for disease identification studies (7).